NCT00089245: Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Refractory, Recurrent, or Advanced CNS or Leptomeningeal Cancer

NCT00089245
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER++, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Ph+ase 1
Drug Category: Therapeutic Antibody, Immunotherapy

Key Eligibility Criteria:

Gender: All
Age: Child, Adult, Older Adult
Location of Metastases: Brain, Leptomeningeal Disease
Additional Notes: Patients must have CNS/ Leptomeningeal disease
Exclusions: 
https://ClinicalTrials.gov/show/NCT00089245

Comments are closed.

Up ↑